The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Aug. 27, 2013
Filed:
May. 09, 2011
Seungkwon You, Yongin-si, KR;
Jai-hee Moon, Seoul, KR;
Jun Sung Kim, Guri-si, KR;
Byung Sun Yoon, Seoul, KR;
Jung Han Lee, Seoul, KR;
Eun Kyoung Jun, Seongnam-si, KR;
June Seok Heo, Seoul, KR;
Ji Hyun Kim, Seoul, KR;
Ji Hye Hwang, Bucheon-si, KR;
Su Hyun Gwon, Bucheon-si, KR;
Seungkwon You, Yongin-si, KR;
Jai-Hee Moon, Seoul, KR;
Jun Sung Kim, Guri-si, KR;
Byung Sun Yoon, Seoul, KR;
Jung Han Lee, Seoul, KR;
Eun Kyoung Jun, Seongnam-si, KR;
June Seok Heo, Seoul, KR;
Ji Hyun Kim, Seoul, KR;
Ji Hye Hwang, Bucheon-si, KR;
Su Hyun Gwon, Bucheon-si, KR;
Abstract
Provided is a composition for reprogramming somatic cells to generate embryonic stem cell-like cells, comprising: a) a Bmi1 (B cell-specific Moloney murine leukemia virus integration site 1) protein or a nucleic acid molecule encoding the Bmi1 protein; and b) at least one low molecular weight substance selected from the group consisting of a set of a MEK/ERK (mitogen-activated protein kinase/extracellular regulated kinase) inhibitor and a GSK (glycogen synthase kinase) inhibitor, a set of a G9a HMTase (G9a histone methyltransferase) inhibitor and a DMNT (DNA methyltransferase) inhibitor, and a histone deacetylase inhibitor. Also, a method is provided for reprogramming somatic cells to generate embryonic stem cell-like cells using the composition. In addition to reducing the number of the reprogramming factors conventionally needed, the composition and method allow the generation of pluripotent embryonic stem cell-like cells which have high potential in the cell therapy of various diseases.